OptiNose Inc (NASDAQ:OPTN) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as $8.64 and last traded at $8.72, with a volume of 5101 shares changing hands. The stock had previously closed at $9.10.
OPTN has been the topic of a number of research analyst reports. Cantor Fitzgerald set a $30.00 price target on OptiNose and gave the company a “buy” rating in a report on Tuesday, August 14th. Piper Jaffray Companies set a $30.00 price target on OptiNose and gave the company a “buy” rating in a report on Tuesday, August 14th. BMO Capital Markets lowered their price target on OptiNose from $30.00 to $28.00 and set an “outperform” rating on the stock in a report on Wednesday, August 15th. Finally, Zacks Investment Research downgraded OptiNose from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $28.75.
The firm has a market cap of $375.17 million and a PE ratio of -1.53. The company has a quick ratio of 10.13, a current ratio of 10.44 and a debt-to-equity ratio of 0.51.
OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.11. The firm had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $1.57 million. As a group, equities analysts predict that OptiNose Inc will post -2.9 EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of OPTN. Thompson Davis & CO. Inc. purchased a new stake in OptiNose during the second quarter valued at $105,000. Summit Trail Advisors LLC purchased a new stake in OptiNose during the second quarter valued at $109,000. MetLife Investment Advisors LLC purchased a new stake in OptiNose during the third quarter valued at $157,000. Dynamic Technology Lab Private Ltd purchased a new stake in OptiNose during the third quarter valued at $230,000. Finally, Sio Capital Management LLC purchased a new stake in OptiNose during the third quarter valued at $336,000. Institutional investors own 47.81% of the company’s stock.
About OptiNose (NASDAQ:OPTN)
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
See Also: Cost of Equity
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.